Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
Fate Therapeutics (FATE) Stock Price & Analysis
1,094 Followers
FATE Stock Chart & Stats
Day’s Range$4.67 - $4.92
52-Week Range― - ―
Previous Close$4.79
Volume1.43M
Average Volume (3M)N/A
Market Cap
$545.18M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 01, 2024EPS Estimate
-$0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.27Price Target Upside52.09% Upside
Rating ConsensusHold
Number of Analyst Covering15
Fate Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentRecent case studies show that CD19 CAR-T therapy could have curative capabilities for severe SLE patients, potentially de-risking FATE's position.
Financial HealthFate ended the year with a significant cash reserve, providing an operational runway well into the future, which reflects the company's financial stability.
Upcoming MilestonesInitial data from clinical studies on key drug programs are expected soon, which could serve as major catalysts for the company's stock performance.
Bears Say
Clinical ValidationFATE’s induced pluripotent stem cell (iPSC) platform has yet to be clinically validated, especially on the manufacturing front.
Market CompetitionThe market for CD19 CAR-T therapies is saturated with multiple companies at similar stages of development, taking a conservative view on FATE's FT819.
Product DevelopmentThe pace of data release for FATE's oncology focus was slower than investors wanted, leading to a shift towards autoimmune disorders.
---
Ownership Overview
25.00% Insiders
21.80% Mutual Funds
15.00% Other Institutional Investors
38.20% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FATE FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Fate Therapeutics’s market cap?
Currently, no data Available
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is May 01, 2024 which is in 8 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Feb 26, 2024. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.522 by $0.072.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -$0.48.
How many shares outstanding does Fate Therapeutics have?
Currently, no data Available
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.522. Following the earnings report the stock price went up 7.338%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Among the largest hedge funds holding Fate Therapeutics’s share is Grosvenor Holdings, L.L.C.. It holds Fate Therapeutics’s shares valued at 4M.
---
Fate Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.27 (52.09% Upside)
$7.27 (52.09% Upside)
Blogger Sentiment
Bearish
FATE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 383.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.15%
12-Months-Change
Fundamentals
Return on Equity
-37.76%
Trailing 12-Months
Asset Growth
-28.25%
Trailing 12-Months
Company Description
Fate Therapeutics
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
---
FATE Earnings Call
Q4 2024
0:00 / 0:00
---
FATE Stock 12 Months Forecast
Average Price Target
$7.27
▲(52.09% Upside)
Technical Analysis
Best Analysts Covering FATE
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
+6.85%
reiterated a buy rating 30 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +6.85% per trade.
---